Equitable Access: Examining Discriminatory & Restrictive Practices in Prescription Drug Formularies

Oct 24, 2023

Executive Summary (Full Report – PDF) Modern formularies initially emerged in the 1980s and 1990s as tools for managing prescription drug costs within healthcare institutions. However, significant changes occurred after the passage of the Affordable Care Act...

Patient Group Releases Special Report: CMS vs FDA: How Medicare and Medicaid Coverage Decisions Limit Patient Access

Jul 20, 2023

New report analyzes the patient impact of growing coverage restrictions for FDA accelerated approval treatments. WASHINGTON — Patients Rising, a non-profit organization that champions patients with chronic and rare diseases, today released a special report titled CMS...

The Alzheimer’s Dilemma: Government and Private Payers Must Evolve or Die

Mar 20, 2023

By MacKay Jimeson In a proclamation last year, President Joe Biden said, “in the next 30 years, the number of Americans with Alzheimer’s is expected to reach nearly 14 million, straining families and our health care system. Fortunately, we are on the cusp of...

This Rare Disease Day we need to go beyond raising awareness and move towards tangible policy and regulatory action.

Feb 28, 2023

By MacKay Jimeson Too many patients and families are in crisis as we mark another Rare Disease Day. Policymakers are focused on debates on Accelerated Approval and drug pricing, while many patients are without treatment due to regulatory or insurance coverage...

PRESS RELEASE: Patient Group Releases Special Report on Biosimilar Market and Trends

Jan 25, 2023

New report analyzes patient impact of game-changing biosimilars, including the introduction of competing biosimilars for Humira WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare diseases, today released its...